Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A retrospective observational study evaluating hypoglycaemia rates in people with type 2 diabetes (T2DM) prescribed basal insulin (BI) analogues

Next Previous
X
Search
Trial Profile

A retrospective observational study evaluating hypoglycaemia rates in people with type 2 diabetes (T2DM) prescribed basal insulin (BI) analogues

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Jan 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin glargine (Primary) ; Insulin glargine (Primary) ; Insulin degludec; Insulin detemir
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms LIGHTNING

    • Most Recent Events

    • 11 Jun 2019 Results of the exploratory analysis assessing those data-driven subgroups in which predicted severe hypoglycemia rates were lower with Gla-300 vs. IDeg, presented at the 79th Annual Scientific Sessions of the American Diabetes Association
    • 05 Oct 2018 Results assessing hypoglycaemic events (n=112,626) presented at the 54th Annual Meeting of the European Association for the Study of Diabetes
    • 12 Dec 2017 Results from LIGHTNING and Deliver D studies published in a Sanofi media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top